Switch theme
Sign up to access all valuation multiples
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.
2007
3.1K+
LTM Revenue $346M
LTM EBITDA $121M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eris Lifesciences has a last 12-month revenue of $346M and a last 12-month EBITDA of $121M.
In the most recent fiscal year, Eris Lifesciences achieved revenue of $231M and an EBITDA of $81.1M.
Eris Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eris Lifesciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $193M | $231M | XXX | XXX | XXX |
| Gross Profit | $124M | $152M | XXX | XXX | XXX |
| Gross Margin | 64% | 66% | XXX | XXX | XXX |
| EBITDA | $63.6M | $81.1M | XXX | XXX | XXX |
| EBITDA Margin | 33% | 35% | XXX | XXX | XXX |
| Net Profit | $47.2M | $44.4M | XXX | XXX | XXX |
| Net Margin | 24% | 19% | XXX | XXX | XXX |
| Net Debt | n/a | $89.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Eris Lifesciences's stock price is INR 1384 (or $16).
Eris Lifesciences has current market cap of INR 189B (or $2.2B), and EV of INR 213B (or $2.5B).
See Eris Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.2B | XXX | XXX | XXX | XXX | $0.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Eris Lifesciences has market cap of $2.2B and EV of $2.5B.
Eris Lifesciences's trades at 7.2x LTM EV/Revenue multiple, and 20.5x LTM EBITDA.
Analysts estimate Eris Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Eris Lifesciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | 22.4x | XXX | XXX | XXX |
| P/E | 49.2x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | -74.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEris Lifesciences's NTM/LTM revenue growth is 14%
Eris Lifesciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $42K for the same period.
Over next 12 months, Eris Lifesciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Eris Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Eris Lifesciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 49% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $42K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 56% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eris Lifesciences acquired XXX companies to date.
Last acquisition by Eris Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Eris Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Eris Lifesciences founded? | Eris Lifesciences was founded in 2007. |
| Where is Eris Lifesciences headquartered? | Eris Lifesciences is headquartered in India. |
| How many employees does Eris Lifesciences have? | As of today, Eris Lifesciences has 3.1K+ employees. |
| Is Eris Lifesciences publicy listed? | Yes, Eris Lifesciences is a public company listed on BOM. |
| What is the stock symbol of Eris Lifesciences? | Eris Lifesciences trades under 540596 ticker. |
| When did Eris Lifesciences go public? | Eris Lifesciences went public in 2017. |
| Who are competitors of Eris Lifesciences? | Similar companies to Eris Lifesciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Eris Lifesciences? | Eris Lifesciences's current market cap is $2.2B |
| What is the current revenue of Eris Lifesciences? | Eris Lifesciences's last 12-month revenue is $346M. |
| What is the current EBITDA of Eris Lifesciences? | Eris Lifesciences's last 12-month EBITDA is $121M. |
| What is the current EV/Revenue multiple of Eris Lifesciences? | Current revenue multiple of Eris Lifesciences is 7.2x. |
| What is the current EV/EBITDA multiple of Eris Lifesciences? | Current EBITDA multiple of Eris Lifesciences is 20.5x. |
| What is the current revenue growth of Eris Lifesciences? | Eris Lifesciences revenue growth between 2023 and 2024 was 20%. |
| Is Eris Lifesciences profitable? | Yes, Eris Lifesciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
